Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2016.57.343
B-type natriuretic peptide: powerful predictor of endstage chronic heart failure in individuals with systolic dysfunction of the systemic right ventricle
Marketa Hegarova
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Jaroslav Brotanek
; Department of Internal Medicine, Thomayer Hospital, Prague, Czech Republic
Milos Kubanek
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Radka Kockova
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Janka Franekova
; Department of Laboratory Methods, Institute for Clinical andExperimental Medicine, PragueCzech Republic
Vera Lanska
; Department of Biostatistics, Institute for Clinical andExperimental Medicine, Prague,Czech Republic
Ivan Netuka
; Department of Cardiac Surgery, Institute for Clinical andExperimental Medicine, Prague,Czech Republic
Vojtech Melenovsky
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Ivan Malek
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Josef Kautzner
; Department of Cardiology, Institute for Clinical andExperimental Medicine, Prague, Czech Republic
Sažetak
Aim To assess whether B-type natriuretic peptide (BNP)
can serve as a predictor of end-stage chronic heart failure
(CHF) in patients with severe systolic dysfunction of the
systemic right ventricle (SRV).
Methods We performed a retrospective analysis in 28 patients
with severe systolic dysfunction of the SRV (ejection
fraction 23 ± 6%) who were evaluated as heart transplant
(HTx) candidates between May 2007 and October 2014.
The primary endpoints of the study (end-stage CHF) were
progressive CHF, urgent HTx, and ventricular assist device
(VAD) implantation. Plasma BNP levels were measured using
a chemiluminescent immunoassay.
Results During median follow-up of 29 months (interquartile
range, 9-50), 3 patients died of progressive CHF, 5
patients required an urgent HTx, and 6 patients underwent
VAD implantation. BNP was a strong predictor of end-stage
CHF (hazard ratio per 100 ng/L: 1.079, 95% confidence interval,
1.042-1.117, P<0.001). The following variables with
corresponding areas under the curve (AUC) were identified
as the most significant predictors of end-stage CHF:
BNP (AUC 1.00), New York Heart Association functional
class class III or IV (AUC 0.98), decompensated CHF in the
last year (AUC 0.96), and systolic dysfunction of the subpulmonal
ventricle (AUC 0.96).
Conclusion BNP is a powerful predictor of end-stage CHF
in individuals with systolic dysfunction of the SRV.
Ključne riječi
Hrčak ID:
170336
URI
Datum izdavanja:
15.8.2016.
Posjeta: 774 *